Closely-held Satsuma Pharmaceuticals dosed the first patient in its Phase 3 efficacy trial of STS101 for the acute treatment of migraine. STS101 is a drug-device combination of dihydroergotamine mesylate (DHE) dry...
BeyondSpring (NASDAQ: BYSI) plans to present positive data in an abstract titled, “Quality of Life (QoL) in Advanced NSCLC Patients Treated with Docetaxel and with Either Plinabulin or Pegfilgrastim for the Prevention...
Eiger BioPharmaceuticals’ (NASDAQ:EIGR) peginterferon lambda (lambda) received FDA breakthrough therapy designation for the treatment of hepatitis delta virus (HDV) infection. HDV is the most severe form of human viral...
Zenabis Global (TSX:ZENA) signed definitive documentation for $25-million of new senior secured debt financing from R.C. Morris Capital Management. The financing involved amending and restating the debenture...
Cerecor (NASDAQ:CERC) received FDA fast track designation for CERC-802 for the treatment of mannose-phosphate isomerase deficiency, also known as CDG-1b. CDG-1b is a rare genetic disease that impacts carbohydrate...
Outlook Therapeutics (NASDAQ:OTLK) completed patient enrollment in its Phase 3 clinical trial comparing ONS-5010 to ranibizumab for the treatment of wet age-related macular degeneration (AMD). Administered via...
Myovant Sciences (NASDAQ:MYOV) completed patient recruitment for its first of two Phase 3 studies of relugolix combination therapy for the treatment of endometriosis-associated pain. Relugolix is a once daily, oral...
iBio (NYSE AMERICAN:IBIO) entered into an agreement with Lung Biotechnology, a subsidiary of United Therapeutics (NASDAQ:UTHR), to produce recombinant human collagen (rhCollagen)-based bioink for 3D bioprinted organ...
In a new report, GMP Securities analyst Justin Keywood gives high marks to Zenabis Global’s (TSX:ZENA) strategy for becoming a leading cannabis producer in Canada. “We see Zenabis as becoming a top-five Canadian...